Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths. We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC. 📄 @JCO_ASCO

🚨🚨Randomized Trial #ASTRO26 Small Cell Lung Cancer Brain Met fractionated SRS vs HA-WBRT 🚨 • No diff time to cognitive failure, neurologic death • SRS ↑↑ OS • ↑↑ AEs HA-WBRT • SRS standard of care SCLC brain met

Proud of our @nyulangone Dean (and prior @Perlmutter_CC Director) Alec Kimmelman for his @Nature paper today: Hepatocytes promote liver metastasis of #PancreaticCancer by providing serine nature.com/articles/s41586-0… With @BarDafna @RichPossemato @KoelinaG @nyugrossman

📜 In @JNCI_Now, we present "A phase II randomized study of proton therapy vs intensity-modulated radiation therapy in patients with unilateral head and neck cancer" Thank you Drs @imrtlee @xrtGenomics & team @MSKCancerCenter @MiamiCancerInst @MayoRadOnc pubmed.ncbi.nlm.nih.gov/4269…

🙏Thanks @crisbergerot for the mention. #CURB2 @CDNCancerTrials needs everyone's support to answer this crucial question. @NRGonc @ALLIANCE_org @SWOG @KHigginsMD @JAMRadOnc @DrAryaAmini @DrMengWelliver @DrewMoghanaki @NCICancerTrials @lungoncdoc @NarjustFlorezMD

We have waited more than a decade for this: ROAM is presented in Rome #EANO2026! See the results of ROAM/EORTC-1308, now also published in @TheLancet! @EANOassociation thelancet.com/journals/lance…

🏆IASLC Cancer Care Team Award Europe🏆 What a special moment at the @IASLC #WCLC2026 in Seoul! I am incredibly proud that our multidisciplinary team has been honoured with the @IASLC Cancer Care Team Award for Europe. This recognition reflects what truly defines modern cancer care: close collaboration across disciplines and professions, combining different perspectives and expertise with one common goal - providing the best possible care for our patients. I am very grateful to share this recognition with an outstanding team: @HillingerSven , Annegret Hinkelmann, Albana Rexhepaj, @raph_werner, @jonas_willmann, Laura Boos, Gian-Marco Monsch, @OliviaLauk, @SilviaUlrich6, Carolin Steinack, Andreas Wicki, Caroline Hertler, @UszDidi, Ömer Senbaklavaci, @Mat_Guc This award belongs to the entire team and represents the dedication, trust and interdisciplinary collaboration that make comprehensive cancer care possible every day. I am deeply grateful for this recognition and very proud of what we have achieved together. #WCLC2026 #IASLC #CancerCareTeamAwardEurope #LungCancer #ThoracicOncology #MultidisciplinaryCare #Teamwork #ThoracicSurgery

Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter. “AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK. Full press release: mskcc.org/news-releases/mskc…

Wonderful memories of #WCLC26 -so good to connect with my international colleagues and 🌎friends working together to fight #lungcancer ❤️. Safe travels ✈️ home! #radonc

Highlighted Studies at #WCLC26 1️⃣ HARMONi-2 In treatment-naïve, advanced NSCLC with PD-L1 ≥1%, ivonescimab improved PFS (11.1 vs 5.8 months; HR 0.51) and OS (30.8 vs 22.6 months; HR 0.73) compared with pembrolizumab. This is a genuinely positive trial, but it does not tell the same story for all PD-L1-positive patients. The OS benefit was clear in the ≥50% subgroup, whereas the HR was 0.85 with a confidence interval crossing 1 in the 1–49% subgroup. Moreover, pembrolizumab monotherapy is not the real comparator for most patients in this group; chemo-IO is. 2️⃣ SWOG S1827/MAVERICK In patients with SCLC who had completed initial treatment and had no brain metastases, MRI surveillance was compared with MRI plus PCI. MRI alone reduced the risk of cognitive failure or death (HR 0.60); grade ≥3 toxicity was 0.8% vs 7.9%. Interim OS and brain metastasis-free survival were not different. The study does not show that MRI prevents brain metastases more effectively. It shows that adding PCI has so far caused cognitive and serious toxicity without demonstrating a survival benefit. If regular MRI and prompt salvage treatment can be provided, routine PCI is now difficult to justify. Still, it is too early to say that PCI is completely dead before the final OS analysis. 3️⃣ TAISHAN-302 In relapsed SCLC, the B7-H3 ADC Tam-Peli improved OS from 9.4 to 13.3 months versus topotecan (HR 0.46); PFS was 7.4 vs 2.8 months and ORR was 59% vs 10%. Grade ≥3 treatment-related toxicity was also lower. ARTEMIS-008 In relapsed SCLC, another B7-H3 ADC, Ris-Rez, also outperformed topotecan: OS was 18.5 vs 10.3 months (HR 0.46), PFS was 7.2 vs 3.0 months, and ORR was 58% vs 13%. Together with TAISHAN-302, this result strongly confirms that B7-H3 is a genuine target in SCLC. However, the median OS figures from the two trials cannot be used to conclude that Ris-Rez is better. The choice between the two ADCs may be determined more by ILD, hematologic toxicity, and ease of administration than by efficacy figures. The efficacy of either agent after tarlatamab maintenance also remains unknown. 5️⃣ EVOKE-03/KEYNOTE-D46 In metastatic NSCLC with PD-L1 ≥50%, sacituzumab govitecan plus pembrolizumab increased ORR compared with pembrolizumab (%56 vs 44%) and numerically prolonged PFS, but the prespecified statistical threshold was not met. OS was 21.5 vs 22.8 months, duration of response was almost identical, and grade ≥3 toxicity was 56% vs 17%. Adding the ADC shrank tumors in more patients but did not change the natural course of the disease. Considering the similar duration of response, lack of OS benefit, and substantial toxicity, this combination has no place in clinical practice.

Presented at #WCLC26: Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF @IASLC

Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm. The end of the PCI era.

🚨 We’re hiring at MSK! 🎯 Director, Metastatic Disease Team 👥 Lead ~20 faculty 🧪 Drive innovative trials 🔬 ~50% research time (track-dependent) 🌐 Shape care across @MSKCancerCenter Help define what’s next in @MSK_RadOnc. 🚀 Contact @seanmmcbride if interested. Click here for more details: msk.wd108.myworkdayjobs.com/…

As #WCLC26 attendees get excited for updates about novel drug combinations for stage III NSCLC before/after surgery, a reminder that the in-field progression rate after CRT is only in the SINGLE DIGITS. A statistic that needs to be on the table whenever a surgical management plan is being considered for clinical N2 disease. Particularly given the LRF rate after complex resections can be as high as 20%. @JoeChangMD @CoreyLangerMD

Could adding another drug improve treatment for stage 3 #lungcancer? In this early trial, people whose cancer could not be removed by surgery received canakinumab alongside chemotherapy, radiotherapy & durvalumab. Of the 32 people assessed, 67% were alive without their cancer getting worse after 2 years. The results are promising, but the study was small & did not compare the treatment with standard care alone. A larger trial is needed. nature.com/articles/s41467-0… #LCSM

HUGE news. Perhaps one of the most important top line results for a common solid tumor. Looking forward to the data @OncoAlert

📄 Our study on national health systems and lung cancer mortality is out in @journal_CHEST. Health spending, nursing workforce, universal coverage & radiotherapy capacity were each linked to better survival across 185 countries. (DM us for the full manuscript.) #GlobalOncology #ReadTheCORGI #CORGILab #lcsm 8/ journal.chestnet.org/article…

@Mat_Guc presenting upcoming publication with first meta analysis of OMD with SBRT showing PFS and OS benefit @ESTRO_RT meets Asia 2026

If the adult thymus matters, should we be protecting it during cancer treatment? Our new study suggests that radiation exposure to the thymus is associated with worse outcomes. Perhaps we should not only target the tumor, but also protect the immune system that helps fight it.

🔥Safety and security of large language models in healthcare 🆙 @Nature 🎯Key threats: data poisoning, prompt injection, hallucination, bias & sycophancy — with current mitigation strategies 🎯Human oversight & regulatory enforcement essential for safe LLM clinical adoption 🎙 @JClusmann @jnkath @OncoAlert @Larvol nature.com/articles/s41586-0…

📄 Our study using machine learning to find country-specific drivers of cancer outcomes is in @Annals_Oncology. The tools that most improve survival differ by country — and we map which lever matters where. #GlobalOncology #ReadTheCORGI #CORGILab 9/ annalsofoncology.org/article…